Magnetic particle imaging

Magnetic particle imaging (MPI) is an emerging non-invasive tomographic technique that directly detects superparamagnetic nanoparticle tracers. The technology has potential applications in diagnostic imaging and material science. Currently, it is used in medical research to measure the 3-D location and concentration of nanoparticles. Imaging does not use ionizing radiation and can produce a signal at any depth within the body. MPI was first conceived in 2001 by scientists working at the Royal Philips Research lab in Hamburg. The first system was established and reported in 2005. Since then, the technology has been advanced by academic researchers at several universities around the world. The first commercial MPI scanners have recently become available from Magnetic Insight and Bruker Biospin.

The hardware used for MPI is very different from MRI. MPI systems use changing magnetic fields to generate a signal from superparamagnetic iron oxide (SPIO) nanoparticles. These fields are specifically designed to produce a single magnetic field free region. A signal is only generated in this region. An image is generated by moving this region across a sample. Since there is no natural SPIO in tissue, a signal is only detected from the administered tracer. This provides images without background. MPI is often used in combination with anatomical imaging techniques (such as CT or MRI) providing information on the location of the tracer.

Applications

Magnetic particle imaging combines high tracer sensitivity with submillimeter resolution. Imaging is performed in a range of milliseconds to seconds. The iron oxide tracer used with MPI are cleared naturally by the body through the mononuclear phagocyte system. The iron oxide nanoparticles are broken down in the liver, where the iron is stored and used to produce hemoglobin. SPIOs have previously been used in humans for iron supplementation and liver imaging.

Blood pool imaging

Cardiovascular

The first in vivo MPI results provided images of a beating mouse heart in 2009. With further research, this could eventually be used for real-time cardiac imaging.[1]

Oncology

MPI has numerous applications to the field of oncology research. Accumulation of a tracer within solid tumors can occur through the enhanced permeability and retention effect. This has been successfully used to detect tumor sites within rats.[2] The high sensitivity of the technique means it may also be possible to image micro-metastasis through the development of nanoparticles targeted to cancer cells. MPI is being investigated as a clinical alternative screening technique to nuclear medicine in order to reduce radiation exposure in at-risk populations.

Cell tracking

By tagging therapeutic cells with iron oxide nanoparticles, MPI allows them to tracked throughout the body. This has applications in regenerative medicine and cancer immunotherapy. Imaging can be used to improve the success of stem cell therapy by following the movement of these cells in the body.[3] The tracer is stable while tagged to a cell and remains detectable past 87 days.[4]

Superparamagnetic tracer

The SPIO tracer used in magnetic particle imaging is detectable within biological fluids, such as the blood. This fluid is very responsive to even weak magnetic fields, and all of the magnetic moments will line up in the direction of an induced magnetic field. These particles can be used because the human body does not contain anything which will create magnetic interference in imaging. As the sole tracer, the properties of SPIONs are of key importance to the signal intensity and resolution of MPI. Iron oxide nanoparticles, due to their magnetic dipoles, exhibit a spontaneous magnetization that can be controlled by an applied magnetic field. Therefore, the performance of SPIONs in MPI is critically dependent on their magnetic properties, such as saturation magnetization, magnetic diameter, and relaxation mechanism. The figure to the right is a representative image of a Point Spread Function (PSF) obtained using Relax Mode in MPI scanner, pointing out the signal intensity and full width at half maximum (FWHM) which corresponds to the signal resolution. Upon application of an external magnetic field, the relaxation of SPIONs can be governed by two mechanisms, Néel, and Brownian relaxation. When the entire particle rotates with respect to the environment, it is following Brownian relaxation, which is affected by the physical diameter. When only the magnetic dipole rotates within the particles, the mechanism is called Néel relaxation, which is affected by the magnetic diameter. According to the Langevin model of superparamagnetism, the spatial resolution of MPI should improve cubically with the magnetics diameter, which can be obtained by fitting magnetization versus magnetic field curve to a Langevin model.[5] However, more recent calculations suggest that there exists an optimal SPIONs magnetic size range (~26 nm) for MPI.[6] This is because of blurring caused by Brownian relaxation of large magnetics size SPIONs. Although magnetic size critically affects the MPI performance, it is often poorly analyzed in publications reporting applications of MPI using SPIONs. Often, commercially available tracers or home-made tracers are used without thorough magnetic characterization. Importantly, due to spin canting and disorder at the surface, or due to the formation of mixed-phase nanoparticles, the equivalent magnetic diameter can be smaller than the physical diameter. And magnetic diameter is critical because of the response of particles to an applied magnetic field dependent on the magnetic diameter, not physical diameter. The largest equivalent magnetic diameter can be the same as the physical diameter. A recent review paper by Chandrasekharan et al. summarizes properties of various iron oxide contrast agents and their MPI performance measured using their in-house Magnetic Particle Spectrometer, shown in the picture here. It should be pointed out that the core diameter listed in the table is not necessarily the magnetic diameter. The table provides a comparison of all current published SPIONs for MPI contrast agents. As seen in the table, LS017, with a SPION core size of 28.7 nm and synthesized through heating up thermal decomposition with post-synthesis oxidation, has the best resolution compared with others with lower core size. Resovist® (Ferucarbotran), consisting of iron oxide made via coprecipitation, is the most commonly used and commercially available tracer. However, as suggested by Gleich et al., only 3% of the total iron mass from Resovist® contributes to the MPI signal due to its polydispersity, leading to relatively low MPI sensitivity. The signal intensity of MPI is influenced by both the magnetic core diameter and the size distribution of SPIONs. Comparing the MPI sensitivity listed in the above table, LS017 has the highest signal intensity (54.57 V/g of Fe) as particles are monodisperse and possess a large magnetic diameter compared with others.

The surface coating of SPIONs is of key importance as well, since it influences the stability, pharmacokinetics behavior, and biodistribution of particles in biological environments. The biodistribution of carboxy-dextran and PEG-modified SPIONs were studied by Keselman et al. using MPI. Results suggested that PEG-modified SPIONs had a relatively long blood half-life of 4.2 h before uptake by the liver and spleen, compared with carboxy-dextran coated SPIONs which cleared rapidly to the liver. The choice of surface coating influences the potential applications using MPI. A carboxy-dextran coated SPION is useful for imaging of liver while PEG-modified particles are more preferred for long-term circulation.

Taking all these concepts and information into consideration, we can begin to define that the “ideal” particles in the context of producing better MPI sensitivity and resolution should possess the following characteristics:

  • magnetic core size around 26 nm and close to the physical diameter
  • monodisperse
  • suitable surface coating

Advantages
  • High resolution (~0.4 mm)
  • Fast image results (~20 ms)
  • No radiation
  • No iodine
  • No background noise (high contrast)

Congresses, workshops
gollark: Well, it has a low confidence score.
gollark: No idea.
gollark: It seems that the bot is "apified".
gollark: ++magic reload_ext search
gollark: Oh *no*, did I forget to set max_workers?

References
  1. Weizenecker, J.; Gleich, B.; Rahmer, J.; Dahnke, H.; Borgert, J. (2009-01-01). "Three-dimensional real-time in vivo magnetic particle imaging". Physics in Medicine and Biology. 54 (5): L1–L10. Bibcode:2009PMB....54L...1W. doi:10.1088/0031-9155/54/5/L01. ISSN 0031-9155. PMID 19204385.
  2. Yu, Elaine Y.; Bishop, Mindy; Zheng, Bo; Ferguson, R. Matthew; Khandhar, Amit P.; Kemp, Scott J.; Krishnan, Kannan M.; Goodwill, Patrick W.; Conolly, Steven M. (2017-03-08). "Magnetic Particle Imaging: A Novel in Vivo Imaging Platform for Cancer Detection". Nano Letters. 17 (3): 1648–1654. Bibcode:2017NanoL..17.1648Y. doi:10.1021/acs.nanolett.6b04865. ISSN 1530-6984. PMC 5724561. PMID 28206771.
  3. Zheng, Bo; See, Marc P. von; Yu, Elaine; Gunel, Beliz; Lu, Kuan; Vazin, Tandis; Schaffer, David V.; Goodwill, Patrick W.; Conolly, Steven M. (2016). "Quantitative Magnetic Particle Imaging Monitors the Transplantation, Biodistribution, and Clearance of Stem Cells In Vivo". Theranostics. 6 (3): 291–301. doi:10.7150/thno.13728. PMC 4737718. PMID 26909106.
  4. Zheng, Bo; Vazin, Tandis; Goodwill, Patrick W.; Conway, Anthony; Verma, Aradhana; Saritas, Emine Ulku; Schaffer, David; Conolly, Steven M. (2015-09-11). "Magnetic Particle Imaging tracks the long-term fate of in vivo neural cell implants with high image contrast". Scientific Reports. 5 (1): 14055. Bibcode:2015NatSR...514055Z. doi:10.1038/srep14055. ISSN 2045-2322. PMC 4566119. PMID 26358296.
  5. Goodwill, Patrick (2012). "X-Space MPI: Magnetic Nanoparticles for Safe Medical Imaging". Advanced Materials. 24 (28).
  6. Chandrasekharan, P (2018). "A perspective on a rapid and radiation-free tracer imaging modality, magnetic particle imaging, with promise for clinical translation". British Journal of Radiology. 91 (1091).

Further reading
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.